GIANT BIOGENE (02367) declined over 5%. As of press time, the stock was down 5.7% to HK$54.6, with turnover reaching HK$560 million.

On the news front, GIANT BIOGENE will hold a board meeting today to approve its interim results for 2025. China Merchants Securities International previously noted that negative media coverage dragged down the company's 618 shopping festival performance, with GMV growth slowing to mid-single-digit percentages year-over-year in May and June. The firm expects the company to achieve revenue and net profit of RMB 3.1 billion and RMB 1.2 billion respectively in the first half of 2025, mainly benefiting from Comfy and Collgene recording sales growth of approximately 25% and over 50% respectively. The target price remains unchanged at HK$77.0.

Caitong Securities believes that Kemei's data showed month-over-month improvement after resuming live streaming in July, and expects sales to gradually recover in the second half of the year.